Fra­zier and Ala­mar Bio­sciences cre­ate im­mune and can­cer biotech At­tovia with $60M in fund­ing

Fra­zier Life Sci­ences is team­ing up with ven­Bio and Il­lu­mi­na Ven­tures to cre­ate a new im­mune-me­di­at­ed and can­cer-fo­cused biotech spun out of the pre­ci­sion pro­teomics com­pa­ny Ala­mar Bio­sciences.

The new com­pa­ny, At­tovia Ther­a­peu­tics, will launch with $60 mil­lion and an ex­clu­sive world­wide li­cense to Ala­mar’s plat­form. The plat­form, called At­to­body, cre­ates small for­mat binders that could be a key piece to an­ti­body-drug con­ju­gates, ra­di­oli­gands and oth­er bio­ther­a­peu­tics. CEO Tao Fu told End­points News that the lead pro­gram, in an undis­closed im­mune-me­di­at­ed dis­ease, will en­ter the clin­ic by 2025.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER